Universität zu Köln

Schwarze-Zander, C., Steffens, B., Emmelkamp, J., Kuemmerle, T., Boesecke, C., Wasmuth, J. C., Strassburg, C. P., Faetkenheuer, G., Rockstroh, J. K. and Eis-Huebinger, A. M. (2016). How successful is influenza vaccination in HIV infected patients? Results from an influenza A(H1N1)pdm09 vaccine study. HIV AIDS Rev., 15 (3). S. 111 - 116. WROCLAW: ELSEVIER URBAN & PARTNER SP Z O O. ISSN 1732-2707

Full text not available from this repository.

Abstract

Aim: To determine immune response after single vaccination with AS03-adjuvanted pandemic H1N1 vaccine in HIV-infected patients. Background: Individuals living with human immunodeficiency virus (HIV) are at risk with influenza due to hyporesponsiveness to influenza vaccine and a higher probability for developing severe disease. Especially, immunogenicity and tolerability of adjuvanted influenza vaccines in a pandemic setting are not well characterized in HIV infected individuals. Methods: Immune response following vaccination with a single dose of influenza A(H1N1)pdm09 AS03-adjuvanted vaccine (H1N1pdm09 vaccine) containing 3.75 mu g hemagglutinin was evaluated in HIV infected individuals by hemagglutination inhibition assay. Tolerability was assessed by questionnaires. Results: Three hundred eighty-nine patients from two German HIV clinics were evaluated. Seroprotection was found in as much as 191/389 (49%) of patients before vaccination. Following vaccination with H1N1pdm09 vaccine seroprotection rate increased to 66% (257/389). Due to high pre-vaccination seroprotection rates seroconversion was only found in a total of 27/389 (7%) of HIV patients. There was no association of seroprotection/seroconversion and current CD4(+) T-cell count, HIV-RNA load in plasma, antiretroviral treatment or demographic factors such as gender, age and ethnicity. The vaccine was overall well tolerated. Conclusions: In this large cohort of HIV infected patients with high baseline H1N1 seroprotective titers only a moderate antibody response to a single vaccination with H1N1pdm09 AS03-adjuvanted vaccine was detected. Emerging influenza pandemics warrant usage of booster vaccinations in order to achieve higher immunogenicity to protect a vulnerable patient population such as HIV positive individuals against influenza. (C) 2016 Polish AIDS Research Society. Published by Elsevier Sp. zo.o. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schwarze-Zander, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Steffens, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Emmelkamp, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuemmerle, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Boesecke, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wasmuth, J. C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Strassburg, C. P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rockstroh, J. K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eis-Huebinger, A. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-288441
DOI:	10.1016/j.hivar.2016.04.002
Journal or Publication Title:	HIV AIDS Rev.
Volume:	15
Number:	3
Page Range:	S. 111 - 116
Date:	2016
Publisher:	ELSEVIER URBAN & PARTNER SP Z O O
Place of Publication:	WROCLAW
ISSN:	1732-2707
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HIV-1-INFECTED PATIENTS; H1N1 INFLUENZA; A H1N1; HUMORAL RESPONSE; IMMUNE-RESPONSE; SPLIT VIRION; IMMUNOGENICITY; INDIVIDUALS; ADULTS; METAANALYSIS Multiple languages Infectious Diseases Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/28844